HOXA5 and acute myeloid leukemia: Elevated IFNγ and T cell inflammation scores in HOXA5-low AML suggest it may predict immunotherapy resistance, potentially explaining differential PD-1 inhibitor efficacy in HOXA5-high tumors (51).